16

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC. Identification of novel peptide safety markers for exocrine pancreatic toxicity induced by cyanohydroxybutene. Toxicol Sci 2007; 96(1):174-83. [More details]

15

Stimac D, Mileti? D, Radi? M, Krznari? I, Mazur-Grbac M, Perkovi? D, et al. The role of nonenhanced magnetic resonance imaging in the early assessment of acute pancreatitis. Am J Gastroenterol 2007; 102(5):997-1004. [More details]

14

Ishii Y, Kohno T, Ito A, Suzuki S, Kohno T, Takayama T, Asai S. Measurement of extra-pancreatic secretory function by 13C-dipeptide breath test. Transl Res 2007; 149(6):298-303. [More details]

13

Pezzilli R, Fantini L. Glucocorticoids and Acute Pancreatitis: Suggestions for Future Clinical Trials. JOP. J Pancreas (Online) 2006; 7(2):249-251. [More details]

12

Paraskeva KD, Karagiannis JA. Assessment of severity and prognosis in patients with acute pancreatitis. CME Gastroenterology, Hepatology & Nutrition 2006; 7(1):6-14. [More details]

11

Saez J, Martinez J, Trigo C, Sanchez-Paya J, Company L, Laveda R, et al. Clinical value of rapid urine trypsinogen-2 test strip, urinary trypsinogen activation peptide, and serum and urinary activation peptide of carboxypeptidase B in acute pancreatitis. World J Gastroenterol 2005; 11(46):7261-5. [More details]

10

Al-Bahrani AZ, Ammori BJ. Clinical laboratory assessment of acute pancreatitis. Clin Chim Acta 2005; 362(1-2):26-48. [More details]

9

Rau B, Schilling MK, Beger HG. Laboratory markers of severe acute pancreatitis. Dig Dis 2004; 22(3):247-57. [More details]

8

Saez J, Martinez J, Trigo C, Sanchez-Paya J, Grino P, Company L, et al. A comparative study of the activation peptide of carboxypeptidase B and trypsinogen as early predictors of the severity of acute pancreatitis. Pancreas 2004; 29(1):e9-14. [More details]

7

Pezzilli R, Venturi M, Morselli-Labate AM, Ceciliato R, Lamparelli MG, Rossi A, et al. Serum trypsinogen activation peptide in the assessment of the diagnosis and severity of acute pancreatic damage: a pilot study using a new determination technique. Pancreas 2004; 29(4):298-305. [More details]

6

Werner J, Hartwig W, Uhl W, Muller C, Buchler MW. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 2003; 3(2):115-27. [More details]

5

Kusnierz-Cabala B, Kedra B, Sierzega M. Current concepts on diagnosis and treatment of acute pancreatitis. Adv Clin Chem 2003; 37:47-81. [More details]

4

Kylänpää-Bäck ML, Kemppainen E, Puolakkainen P. Trypsin-based laboratory methods and carboxypeptidase activation peptide in acute pancreatitis. JOP. J Pancreas (Online) 2002; 3(2):34-48. [More details]

3

Frossard JL, Hadengue A, Pastor CM. New serum markers for the detection of severe acute pancreatitis in humans. Am J Respir Crit Care Med 2001; 164(1):162-70. [More details]

2

Frossard JL. Trypsin activation peptide (TAP) in acute pancreatitis: from pathophysiology to clinical usefulness. JOP. J Pancreas (Online) 2001; 2(2):69-77. [More details]

1

Dervenis C. Assessments of severity and management of acute pancreatitis based on the Santorini consensus conference report. JOP. J Pancreas (Online) 2000; 1(4):178-182. [More details]